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Background: Past clinical studies have shown the relationship between type 2 diabetes (T2D) and obstructive sleep apnoea
(OSA), but little is known about type 1 diabetes (T1D). The purpose of this study is to examine clinical indicators associated
with OSA in patients with different subtypes of diabetes.
Methods: Self-administered questionnaires that asked if the patients had been diagnosed with OSA were distributed to pa-
tients with T1D and T2D. General and clinical information was confirmed with both questionnaires and medical records.
Result: Among the 1,269 T1D patients and 5,838 T2D patients, 20 T1D patients and 421 T2D patients had received a diag-
nosis of OSA. OSA patients were more likely to be male, older, and to have a greater BMI and lower LDLC and HDLC. T1D
patients with OSA were characterized by a significantly higher prevalence of severe hypoglycemia. On the other hand, T2D
patients with OSA had high HbA1c, decreased renal function, high frequency of diabetic neuropathy, and correlated with
macrovascular complications.
Conclusion: The prevalence of OSA was significantly higher in T2D patients. It was suggested that OSA-related pathologies
might differ between T1D and T2D patients.
Key Words: obstructive sleep apnoea, diabetic complications, macrovascular complications, microvascular complications,
diabetes
Introduction
Sleep disturbance associated with sleep apnoea syndrome
is a worldwide social problem.
１
There are three types of
sleep apnoea: obstructive sleep apnoea (OSA), central
sleep apnoea (CSA), and a combination of the two, called
mixed type. OSA is at an increased risk of developing
diabetes,
２
and patients with type 2 diabetes (T2D) are
more likely to have OSA.
３
Diabetes and OSA often de-
velop in the same individuals, suggesting common un-
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derlying mechanisms and bidirectional associations with
each other. OSA is also associated with diabetic retinopa-
thy, neuropathy, and nephropathy. In addition, diabetes
and OSA share a common risk of atherosclerotic vascular
diseases.
Although the seriousness of sleep apnoea in patients
with diabetes has been repeatedly emphasized, most of
these studies were focused on patients with T2D, and in-
formation is lacking regarding the frequency and patho-
physiology of OSA in patients with type 1 diabetes
(T1D). Therefore, we conducted this study to compare
the prevalence of OSA in association with the different
types of diabetes. We also investigated the differences in
the clinical characteristics in patients with OSA between
T1D and T2D.
Materials and Methods
We conducted a single center cross-sectional study as
part of the Diabetes Study from the Diabetes Center of
Tokyo Women’s Medical University (DIACET ) from
January to December in 2014, which was approved on 16
October 2013 by the Ethical Committee of the Tokyo
Women’s Medical University (Approval No. 2481-R )
and written informed consent was obtained from each
subject. In DIACET, a self-administered questionnaire
consisting of several clinical questions was distributed to
patients with diabetes who visited the Diabetes Center of
Tokyo Women’s Medical University Hospital.
In the current study, we used the data from DIACET
2014, in which 7,964 patients, including 3,404 females,
4,560 males, and 1,421 patients with T1D, 6,266 patients
with T2D participated and 277 patients with other type of
diabetes. Among those who responded to this question-
naire, patients undergoing haemodialysis, those with psy-
chiatric conditions, and those under 15 years of age were
excluded. All procedures followed were in accordance
with the ethical standards of the responsible committee
on human experimentation ( institutional and national )
and with the Helsinki Declaration of 1964 and later ver-
sions.
1. DIACET 2014
In DIACET 2014, we asked the participants whether
they had been diagnosed with OSA in specific examina-
tions. We also asked patients about medication for hyper-
tension and dyslipidaemia, the frequency of severe hypo-
glycaemia, past and current history of smoking and
drinking, history of clinical visits for cardiac diseases,
cerebrovascular disease, or gangrene, and symptoms due
to diabetic autonomic neuropathy. Severe hypoglycaemia
was defined as episodes with hypoglycaemia accompa-
nied by a consciousness disturbance that required assis-
tance from others.
Symptoms due to autonomic neuropathy consisted of
the following 12 symptoms: constipation, diarrhoea, fae-
cal incontinence, orthostatic hypotension, sexual impo-
tence, hyperhidrosis, anhidrosis, frequency urination, dy-
suria, belching, heartburn, and a dull feeling in the stom-
ach. If more than three of these symptoms were present,
we diagnosed the patient with autonomic neuropathy.
2. Other information related to diabetes
General and clinical information, such as age, sex, the
duration of diabetes, body weight, body-mass index
( BMI ) , HbA 1 c, estimated glomerular filtration rate
(eGFR), serum lipid profiles, and the stages of microvas-
cular complications (neuropathy, retinopathy, and neph-
ropathy) were confirmed by reviewing the medical re-
cords.
The presence and stage of diabetic retinopathy was
identified by ophthalmologic examination by ophthal-
mologists according to the International Clinical Diabetic
Retinopathy and Diabetic Macular Edema Disease Sever-
ity Scales.
４
We classified patients into the following three
groups according to the stage of diabetic retinopathy: 1)
no apparent retinopathy, 2) background retinopathy, and
3) pre-proliferative or proliferative retinopathy. The stage
of diabetic nephropathy was evaluated by the urinary al-
bumin/creatinine ratio (ACR) and eGFR as follows: stage
1 (ACR < 30 mg/g and eGFR ≥ 30 mL/min/1.73m2);
stage 2 (ACR 30-299 mg/g and eGFR ≥ 30 mL/min/1.73
m
2
); stage 3 (ACR≥ 300 mg/g and eGFR ≥ 30 mL/min/
1.73 m
2
); and stage 4 (eGFR < 30 mL/min/1.73 m
2
, re-
gardless of ACR level).
５
The stages of chronic kidney
disease (CKD) were classified into the following four
groups according to eGFR: stage 1 (≥ 90 mL/min/1.73
m
2
); stage 2 (60-89 mL/min/1.73 m
2
); stage 3 (30-59 mL/
min /1.73 m
2
) ; and stage 4 ( < 30 mL / min / 1.73 m
2
) .








OSA (n) (%) 20 (1.6) 421 (7.2) <0.0001*
Age (years) 45±14 66±12 <0.0001
Male (n) (%) 425 (33.4) 3,679 (58.3) <0.0001*
Duration of diabetes (years) 20.9±11.8 17.8±11.2 <0.0001
BMI (kg/m2) 22.9±3.3 24.5±4.3 <0.0001
HbA1c (%) 8.1±1.3 7.7±1.3 <0.0001
eGFR (ml/min/1.73 m2) 78.1±24.9 58.2±21.5 <0.0001
Cr (mg/dl) 0.73±0.41 0.89±0.52 <0.0001
ACR (mg/gCr) 6 (4.2-11.0) 12 (6-46) 0.0009
Triglyceride (mg/dl) 81.0 (60-115) 126 (91-175) <0.0001
LDLC (mg/dl) 107.6±24.1 108.5±25.3 0.4583
HDLC (mg/dl) 78.6±19.9 59.0±16.5 <0.0001
Cholesterol-lowering drugs (%) 20 49 <0.0001*
Antihypertensive drugs (%) 28 61 <0.0001*
Severe hypoglycaemia (%) 47 11 <0.0001*
Smoking (%) 14 12 0.0116*
Neuropathy (%) 15 19 0.0004*
Retinopathy
none/background/proliferative (%) 72/14/14 70/17/13 0.0071*
Nephropathy stage 1/2/3-5 (%) 87/9/4 69/22/9 <0.0001*
CKD stage1/2/3/4-5 (%) 29/47/21/3 9/34/50/7 <0.0001*
Ischemic heart disease (%) 2.1 12.7 <0.0001*
Cerebrovascular disease (%) 1.3 5.0 <0.0001*
Diabetic gangrene (%) 0.3 1.3 0.0007*
Student’s t-test, *χ2 or Fisher’s exact probability test, mean ± SD, median (interquartile range).
OSA, obstructive sleep apnoea; BMI, body mass index; eGFR, estimated glomerular filtration 
rate; ACR, albumin/creatinine ratio; LDLC, low-density lipoprotein cholesterol; HDLC, high-
density lipoprotein cholesterol; CKD, chronic kidney disease.
tient suffers from one or more of ischemic heart disease,
cerebrovascular disease and diabetic gangrene.
3. Statistical analysis
Statistical analysis was performed using JMP version
12.0 (OSA Institute Inc., USA). Differences in the con-
tinuous variables between groups were tested with an un-
paired Student’s t-test if the values were normally distrib-
uted or with the Mann-Whitney U test if the values were
not normally distributed. Pearson’s correlation test and
the R
2
(adjusted coefficient of determination) were used
to analyse the relationships between OSA and the other
clinical parameters. Univariate and multiple logistic re-
gression analyses were performed to determine the clini-
cal factors associated with sleep apnoea. The level of sta-
tistical significance was set at p <0.05.
Results
1. Clinical characteristics of the subjects by the
type of diabetes (Table 1)
Among the 7,964 patients who participated in DI-
ACET 2014, 7,107 patients who answered the question
of whether they had a diagnosis of sleep apnoea were
studied. There were 1,269 patients with T1D and 5,838
patients with T2D. The clinical characteristics of the pa-
tients with T1D and T2D are listed in Table 1. In pa-
tients with T1D, the mean age was lower, the duration of
diabetes was longer, the BMI and ACR were lower, and
the HbA1c and eGFR were higher than those in patients
with T2D. Regarding the serum lipid profiles, patients
with T1D had lower triglyceride and higher high-density
lipoprotein cholesterol (HDLC) levels than those in pa-
tients with T2D; there was no significant difference in
the low-density lipoprotein cholesterol (LDLC) levels in
patients with T1D and T2D. In patients with T1D, the
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Table　2　Comparison of the clinical background of patients with and without OSA by the type of diabetes.











Age (years) 56±3 45±1 0.0005 63±0.6 66±0.2 0.0002 0.0058
Male (n) (%) 15 (75) 410 (32.8) 0.0001* 350 (83.1) 3,329 (61.5) <0.0001* 0.3697*
Duration of diabetes (years) 23.3±2.6 20.9±0.3 0.3721 17.0±0.6 17.9±0.2 0.1612 0.0122
BMI (kg/m2) 24.7±0.7 22.8±0.1 0.0130 27.6±0.2 24.2±0.1 <0.0001 0.0143
HbA1c (%) 7.5±0.3 8.1±0.1 0.0644 7.9±0.1 7.7±0.1 0.0018 0.2525
eGFR (ml/min/1.73 m2) 62.7±6.2 78.4±0.8 0.0118 52.3±1.1 58.6±0.3 <0.0001 0.0504
Cr (mg/dL) 0.80±0.10 0.73±0.01 0.5126 1.1±0.1 0.9±0.1 <0.0001 0.2154
ACR (mg/gCr) 3.8 (2.9-9.8) 6.0 (4.1-10.8) 0.6563 17.6 (7.1-86.8) 11.5 (6.0-45.0) 0.0203 0.4417
Triglyceride (mg/dL) 92 (80-133) 81 (59-115) 0.1057 151 (108-211) 125 (90-172) <0.0001 0.1101
LDLC (mg/dL) 92.7±5.7 107.9±0.7 0.0086 102.0±1.3 109.0±0.4 <0.0001 0.1417
HDLC (mg/dL) 66.4±4.7 78.8±0.6 0.0087 52.6±0.9 59.4±0.2 <0.0001 0.0002
Cholesterol-lowering drugs (%) 35 20 0.1271* 55 49 0.0106* 0.0739*
Antihypertensive drugs (%) 45 28 0.1058* 75 61 <0.0001* 0.0054*
Severe hypoglycaemia (%) 70 47 0.0425* 12 12 0.9124* <0.0001*
Smoking (%) 15 14 0.9330* 14 14 0.8604* 1.0000*
Neuropathy (%) 30 15 0.0818* 26 18 0.0002* 0.6869*
Retinopathy 
none/background/proliferative (%) 85/0/15 72/14/14 0.1945* 68/19/13 70/17/13 0.6373* 0.0156*
Nephropathy stage 1/2/3-5 (%) 86/14/0 87/9/4 0.6535* 63/25/12 70/21/9 0.1231* 0.2843*
CKD stage 1/2/3/4-5 (%) 0/50/43/7 30/48/20/2 0.0158* 55/22/2/21 65/18/5/12 0.0006* 0.6660*
Ischemic heart disease (%) 10 2 0.0706* 25.4 11.8 <0.0001* 0.0876*
Cerebrovascular disease (%) 0 1.3 0.4744* 10.2 5.0 <0.0001* 0.0403*
Diabetic gangrene (%) 0 0.3 0.7213* 5.0 1.3 <0.0001* 0.1575*
Student’s t-test, *Chi-square or Fisher’s exact probability test, p*: the comparison of T1D and T2D with OSA.
OSA, obstructive sleep apnoea; BMI, body mass index; eGFR, estimated glomerular filtration rate; ACR, albumin/creatinine ratio; LDLC, low-density 
lipoprotein cholesterol; HDLC, high-density lipoprotein cholesterol; CKD, chronic kidney disease.
use of anti-hyperlipidaemic and antihypertensive drugs
were much lower than that in patients with T2D (p<
0.0001). Forty-seven percent of patients with T1D expe-
rienced severe hypoglycaemia, the prevalence of which
was much higher than that of T2D patients (p<0.0001).
In those with T2D, the prevalence of diabetic microvas-
cular and macrovascular complications was higher than
that in patients with T1D. Among the participants, 20 pa-
tients with T 1 D (1.7%) and 421 patients with T 2 D
(7.2%) reported that they had OSA that had been diag-
nosed by specific examinations. The prevalence was sig-
nificantly higher in patients with T2D than in those with
T1D, with an odds ratio of 4.85 (95% confidence inter-
val: 3.09-7.63, p<0.001) in the univariate logistic regres-
sion analysis.
2. Comparison of the clinical characteristics of pa-
tients with and without OSA (Table 2)
Patients with OSA were more likely to be male, had
higher BMIs and lower levels of HDLC compared to
those in patients without OSA. These findings were simi-
lar when comparing either T1D or T2D patients with
OSA to patients without OSA. Patients with T1D and
OSA were significantly associated with a higher preva-
lence of a history of severe hypoglycaemia (p=0.0425).
In patients with T2D, those with OSA had a higher HbA1
c, lower eGFR, higher prevalence of diabetic neuropathy
and ischaemic heart disease, diabetic gangrene, compared
to those of T2D patients without OSA.
3. Comparison of clinical parameters compared by
the presence or absence of SAS for each type of diabe-
tes (Table 2)
T1D patients with OSA were younger (p=0.0058), had
a longer duration of diabetes (p=0.0122), and had a lower
BMI (p=0.0143) than those of T2D patients with OSA.
The rate of antihypertensive drug use was higher in pa-
tients with T2D than in patients with T1D. Patients with
T1D and OSA experienced more episodes of severe hy-
poglycaemia than those in patients with T2D and OSA.
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Table　3　Linear logistic regression analysis.
Type 1 DM Type 2 DM
OR (95% CI) p OR (95% CI) p
Age 1.05 (1.02-1.08) 0.0008 0.99 (0.98-0.99) 0.0002
Male 6.13 (2.36-19.0) <0.0001 3.09 (2.40-4.04) <0.0001
Duration of diabetes 1.02 (0.98-1.05) 0.3781 0.99 (1.003-1.007) 0.1587
BMI 1.15 (1.02-1.28) 0.0202 1.15 (1.13-1.17) <0.0001
HbA1c 0.66 (0.42-0.99) 0.0419 1.12 (1.04-1.20) 0.0025
eGFR 0.97 (0.95-0.99) 0.0106 0.99 (0.98-0.99) <0.0001
TG 1.00 (0.998-1.004) 0.2768 1.00 (1.002-1.004) <0.0001
LDLC 0.97 (0.95-0.99) 0.0064 0.99 (0.98-0.99) <0.0001
HDLC 0.96 (0.93-0.99) 0.0044 0.97 (0.96-0.98) <0.0001
Cholesterol-lowering drugs 2.13 (0.79-5.26) 0.1271 1.30 (1.06-1.58) 0.0106
Antihypertensive drugs 2.11 (0.85-5.16) 0.1058 1.95 (1.56-2.46) <0.0001
Severe hypoglycaemia 2.59 (1.03-6.48) 0.0425 1.02 (0.72-1.40) 0.9124
Smoking 1.12 (0.31-4.09) 0.9330 0.95 (0.71-1.30) 0.7527
Neuropathy 2.51 (0.88-6.35) 0.0818 1.56 (1.24-1.96) 0.0002
Retinopathy 0.45 (0.10-1.34) 0.2004 1.10 (0.89-1.37) 0.3677
Nephropathy 1.117 (0.06-6.65) 0.9188 1.37 (1.01-1.85) 0.0440
Ischemic heart disease 5.44 (0.83-20.27) 0.0706 2.56 (2.02-3.23) <0.0001
Cerebrovascular disease - - 2.41 (1.70-3.36) <0.0001
Diabetic gangrene - - 5.18 (3.05-8.59) <0.0001
Macrovascular complications 3.11 (0.49-11.27) 0.1932 2.79 (2.25-3.45) <0.0001
OR, odds ratio; CI, confidence interval; TG, triglyceride; BMI, body mass index; eGFR, estimated glomerular 
filtration rate; LDLC, low-density lipoprotein cholesterol; HDLC, high-density lipoprotein cholesterol.
Table　4　Multivariate logistic regression analysis.
OR 95% CI p
Type 1 DM (OSA)
Male 5.40 2.047-16.873 0.0014
Severe hypoglycaemia 2.92 1.132-8.519 0.0338
BMI 1.16 1.26-1.310 0.0147
Age 1.05 1.018-1.085 0.0026
Type 2 DM (OSA)
Diabetic gangrene 4.074 2.219-7.210 2.66×10-6
Male 3.365 2.547-4.514 8.34×10-17
Ischemic heart disease 2.323 1.738-2.982 6.35×10-11
Cerebrovascular disease 1.981 1.335-2.871 4.50×10-4
BMI 1.168 1.144-1.194 4.29×10-46
Independent variables: age, male, BMI, HbA1c, severe hypoglycae-
mia, ischemic heart disease, diabetic gangrene, and cerebrovascular 
disease.
OSA, obstructive sleep apnoea; OR, odds ratio; CI, confidence inter-
val; BMI, body mass index.
Patients with T2D and OSA had more severe retinopathy
than that in patients with T1D and OSA, and the T2D pa-
tients had significantly more cerebrovascular disease than
T1D patients. However, OSA patients with T1D and T2
D did not differ significantly in difference in diabetic
nephropathy, CKD, ischaemic heart disease and diabetic
gangrene.
4. Correlation of OSA and the clinical parameters
(Table 3)
In univariate logistic regression analyses, higher age,
male gender, higher BMI, lower eGFR, LDLC, and
HDLC were associated with a higher odds ratio of OSA
in both patients with T1D and T2D. Severe hypoglycae-
mia and low HbA1c was significantly associated with
OSA only in patients with T1D. High HbA1c, high tri-
glyceride levels, the oral administration of cholesterol-
lowering and antihypertensive drugs, neuropathy, the se-
verity of nephropathy, and ischaemic heart disease, cere-
brovascular disease and diabetic gangrene, were found to
be risk factors for OSA in T2D.
5. Correlation of OSA and the clinical parameters
In the multivariate logistic regression analysis (Ta-
ble 4), male gender, BMI were significantly associated
with the risk of OSA in both patients with T1D and T2D.
Severe hypoglycaemia, and current age were signifi-
cantly associated with the risk of OSA in patients with
T1D. Diabetic gangrene, ischaemic heart disease, and
cerebrovascular disease were found to be associated with
the risk of OSA in patients with T2D. As a result of the
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Table　5　Multivariate logistic regression analysis of all OSA 
patients.
OR 95% CI p
DM type 3.14 1.437-6.846 0.0041
Male 2.91 1.912-4.458 <0.0001
BMI 1.14 1.105-1.177 <0.0001
Ischemic heart disease 1.746 1.156-2.637 0.0081
Cerebrovascular disease 2.427 1.347-4.376 0.0032
Diabetic gangrene 5.613 2.455-12.834 <0.0001
Independent variables: DM type, age, male, duration, BMI, HbA1c, 
smoking, severe hypoglycaemia, neuropathy, retinopathy, ischemic 
heart disease, diabetic gangrene, and cerebrovascular disease.
OSA, obstructive sleep apnoea; OR, odds ratio; CI, confidence in-
terval; DM, diabetes mellitus; BMI, body mass index.
multivariate logistic regression analysis of all patients
(Table 5) , T2D, male, BMI, ischaemic heart disease,
cerebrovascular disease and diabetic gangrene were inde-
pendently associated with OSA.
Discussion
In this study, we identified and compared the clinical
characteristics associated with the risk of OSA in Japa-
nese patients with T1D and T2D and found that the
prevalence of OSA was significantly lower in patients
with T1D than that in patients with T2D. We also found
that in patients with T1D, microvascular or macrovascu-
lar complications were not associated with OSA. In con-
trast, a significant association between severe hypogly-
caemia and OSA was observed in patients with T1D.
Previous studies from Manin et al
６
(67 patients, 60%
male, mean age: 54 ± 10 years; BMI: 25.8 ± 4.7 kg/
m
2
), Borel et al
７
(37 patients, 68% male, mean age: 43±
13 years; BMI: 24.7± 3.0 kg/m2), Banghoej et al８ (199
patients, 68% male, mean age: 52± 15 years; BMI: 25.3
± 3.3 kg/m2) have shown that the prevalence of OSA
was 40-46% and that of severe OSA was 6-19% in T1D.
In our study, the prevalence was much lower. The lower
BMI (22.9± 3.3 kg/m2) in our study may be associated
with the lower incidence of OSA. Obesity has a strong
impact on the onset of OSA, which we also found in this
study. In this study, the mean age (45 ± 14 years) and
male ratio (33.4%) of subjects were lower compared to
previous studies. This character may also, at in part, ex-
plain the difference between the current study and past
studies.
In addition, the information on OSA in our study was
based on the self-assessment of the questionnaire and is
most likely underestimated. To diagnose OSA,
laboratory-based polysomnography is thought to be the
gold standard but is not widely used because of the high
cost and the necessity of hospitalization and skilled tech-
nical experts. For this reason, polysomnography is usu-
ally used for patients who are strongly suspected of hav-
ing OSA. For OSA screening, questionnaires have often
been used, however, using home sleep-monitoring de-
vices is more effective and practical.
９
We found an independent association between OSA
and severe hypoglycaemia in patients with T1D. There
was significant difference in HbA1c between patient with
and without severe hypoglycaemia (HbA1 c 7.9% vs.
8.2%, p=0.0039, data were not shown). OSA in T1D pa-
tients was associated with lower HbA1c level. We do not
have the exact information of the frequency and duration
of severe hypoglycaemia. The mechanism is unknown
and cannot be elucidated from the present study, which
was not designed to investigate causal relations.
The clinical experience and experimental studies show





suggested that OSA might involve in the duration of neu-
ropathy, and OSA was significantly correlated with neu-
ropathy in T1D. In addition, glossoptosis may be associ-
ated with the disturbance of consciousness due to hypo-
glycaemia, which may cause OSA. In this study, we are
unable to find a significant association between OSA and
diabetic neuropathy. One of the reasons for this is may be
that we assessed diabetic neuropathy with a questionnaire
instead of with a physical examination, most likely we
did an underestimation of prevalence of neuropathy. Ele-
vated BMI is a risk factor for OSA also in T1D as the
same with T2D. Mechanism investigation shows that the
resistance of leptin in obesity and diabetes contributes to
OSA, which is involved in the neuro-mechanical control




reported that OSA has a strong effect on is-
chaemic heart disease, and alterations of the cerebral
blood flow have been found in OSA.
１６
In the current
study, BMI, male gender, and a history of ischemic heart
disease and cerebrovascular disease were associated with
OSA in the patients with T2D, which is in line with pre-
vious studies.
１６-１９
Furthermore, diabetic gangrene was
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positively correlated with OSA, suggesting that blood
flow in the legs of OSA patients may be reduced.
Chronic repetitive nocturnal hypoxia leads to endothelial
damage,
２０，２１
and a positive correlation between the carotid
intima media thickness (IMT) and apnoea-hypopnea in-
dex is reported,
２２
OSA has a strong effect on arterioscle-
rosis.
１５
Also, carotid IMT has a relationship with insulin
resistance,
２３
which result in endothelial dysfunction and
atherogenesis.
２４
Even this is still at the stage of hypothe-
sis, but we think the OSA patients with high insulin resis-
tance tend to suffer arteriosclerosis, and cardiovascular
disease.
It has been reported that patients with OSA appear to
have increased dyslipidaemia,
２５
but the mechanism re-
mains unknown. Previous evidence suggests that the
hypoxia-inducible factor-1 in the liver activates sterol
regulatory element-binding protein-1 ( SREBP-1 ) and
stearoyl-coenzyme A desaturase-1 (SCD-1), an important
gene of triglyceride and phospholipids biosynthesis con-
trolled by SREBP-1.
２６
Although many studies have con-
firmed the relationship between OSA and concrete lipid
indexes, the results varied from one to another. It is dem-
onstrated that LDLC was independently associated with
OSA,
２７
severity of OSA were associated with higher tri-




found total cholesterol, LDLC, triglyceride and apo-B in-
creased in patients with OSA. Nonetheless, in this study,
patients with OSA had lower LDLC, higher triglyceride
and lower HDLC compared to those of the other patients.
The oral administration of cholesterol-lowering drugs
such as statin might be the cause of this result, as the pa-
tients who were taking these medicines were the most
likely have to have a lower LDLC.
This study had some limitations. First, the evaluation
of OSA and diabetic complications were performed by
using a self-administered questionnaire, restricting the
validity of the information that was obtained. We have
reviewed medical records and confirmed that patients
who have been diagnosed with OSA really have OSA.
However, in fact, it is possible that an undiagnosed OSA
patient has been missed and the number of cases might
be underestimated. Second, this was a single-center
study, limiting its generalizability. Nonetheless, the in-
clusion of a large population with diabetes, consisting of
more than 7,000 participants, provided more precise in-
formation regarding the association between OSA and
diabetes, especially T1D.
Conclusion
In this single-center cross-sectional study, the prevalence
of OSA was significantly higher in patients with T2D
than that in those with T1D. In patients with T1D, a his-
tory of severe hypoglycaemia was associated with an in-
creased risk of OSA. We confirmed a close association
between macrovascular diseases and OSA in patients
with T2D, which has been shown previously.
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